Referencias►
1.
Langsjoen H, Langsjoen P, Langsjoen P, et al. Usefulness of coenzyme Q
10
in clinical cardiology: a long-term study.
Mol Aspects Med. 1994;15(suppl):S165 - S175.
2.
Langsjoen PH, Vadhanavikit S, Folkers K. Response of patients in classes III and IV of cardiomyopathy to therapy in a blind and crossover trial with coenzyme Q
10.
Proc Natl Acad Sci USA. 1985;82:4240 - 4244.
3.
Poggesi L, Galanti G, Comeglio M, et al. Effect of coenzyme Q
10
on left ventricular function in patients with dilative cardiomyopathy.
Curr Ther Res. 1991;49:878 - 886.
4.
Langsjoen PH, Langsjoen PH, Folkers K. A six-year clinical study of therapy of cardiomyopathy with coenzyme Q
10.
Int J Tissue React7. 1990;12:169 - 171.
5.
Langsjoen PH, Vadhanavikit S, Folkers K. Response of patients in classes III and IV of cardiomyopathy to therapy in a blind and crossover trial with coenzyme Q
10.
Proc Natl Acad Sci USA. 1985;82:4240 - 4244.
6.
Permanetter B, Rossy W, Klein G, et al. Ubiquinone (coenzyme Q
10) in the long-term treatment of idiopathic dilated cardiomyopathy.
Eur Heart J. 1992;13:1528 - 1533.
7.
Spigset O. Reduced effect of warfarin caused by ubidecarenone [letter].
Lancet.
1994;344:1372 - 1373.
8.
Winter S, Jue K, Prochazka J, et al. The role of L-carnitine in pediatric cardiomyopathy.
J Child Neurol. 1995;10(suppl 2):S45 - S51.
9.
Pepine CJ. The therapeutic potential of carnitine in cardiovascular disorders.
Clin Ther. 1991;13:2 - 21.
10.
Bertelli A, Ronca G. Carnitine and coenzyme Q
10: biochemical properties and functions, synergism and complementary action.
Int J Tissue React. 1990;12:183 - 186.
